A case for compassionate use: When unapproved drugs are the only hope
Off-label and Compassionate use of Medications for COVID-19 Treatment
Compassionate Use and other Managed Access Concepts - GMP Journal
Compassionate use: Providing access to much needed treatments | Novartis
Compassionate Use Policy - BioMarin
Manufacturer's Compassionate Use Policies: Companies with Posted Policies More Than Doubled Since September 2016
Compassionate use: Providing access to much needed treatments | Novartis
Regulatory Explainer: FDA's Expanded Access (Compassionate Use) Program | RAPS
Compassionate Use and other Managed Access Concepts - GMP Journal
The Global Guide to Compassionate Use Programs
A case for compassionate use: When unapproved drugs are the only hope
Proportion of Gaucher Patients per country receiving their treatment on... | Download Scientific Diagram
Compassionate Use Navigator Information for Physicians Application Process Overview Apply to a Drug Manufacturer
Compassionate Use Programmes - Paul-Ehrlich-Institut
The EU's compassionate use mechanism for drugs. | Download Table
Compassionate Use Programmes - Paul-Ehrlich-Institut
Legal basis, terminologies, and regulatory evidence for compassionate... | Download Scientific Diagram
Understanding the challenges and ethical aspects of compassionate use of drugs in emergency situations Goyal PK, Mathur R, Medhi B - Indian J Pharmacol
Summary of 'compassionate use' regulations in ten European countries | Download Table
Regeneron Compassionate Use Policy
European Medicines Agency Domenico Scarlattilaan 6 1083 HS Amsterdam The Netherlands Subject: IV Zanamivir Procedure No. EMA/H
Compassionate use - EURORDIS
Egetis receives approval in Turkey for compassionate use of Emcitate® for MCT8 deficiency
